Evaluation of Protein Kinase Inhibitors with PLK4 Cross-Over Potential in a Pre-Clinical Model of Cancer

The multifaceted allosteric regulation of Aurora kinase A

(2018) Nicholas Mark Levinson   BIOCHEMICAL JOURNAL

Emerging therapeutic targets for the treatment of malignant rhabdoid tumors

(2018) Karolina Nemes et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Kinase-targeted cancer therapies: progress, challenges and future directions

(2018) Khushwant S. Bhullar et al.   Molecular Cancer

Centriole Overduplication is the Predominant Mechanism Leading to Centrosome Amplification in Melanoma

(2018) Ryan A. Denu et al.   MOLECULAR CANCER RESEARCH

Clinically Applicable Inhibitors Impacting Genome Stability

(2018) Anu Prakash et al.   MOLECULES

Once and only once: mechanisms of centriole duplication and their deregulation in disease

(2018) Erich A. Nigg et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Downregulation of miR-10B* is correlated with altered expression of mitotic kinases in osteosarcoma

(2018) Gabriela Molinari Roberto et al.   PATHOLOGY RESEARCH AND PRACTICE

Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers

(2018) Masanori Kawakami et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma

(2018) Zuoxin Zhang et al.   CANCER LETTERS

Analysis of centrosome and DNA damage response in PLK4 associated Seckel syndrome

(2017) Tuba Dinçer et al.   EUROPEAN JOURNAL OF HUMAN GENETICS

Kinase targets in CNS drug discovery

(2017) Hendra Gunosewoyo et al.   Future Medicinal Chemistry

Preclinical evaluation of the Aurora kinase inhibitors AMG 900, AZD1152-HQPA, and MK-5108 on SW-872 and 93T449 human liposarcoma cells

(2017) Sandhya Noronha et al.   IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL

Medulloblastoma: From Myth to Molecular

(2017) Vijay Ramaswamy et al.   JOURNAL OF CLINICAL ONCOLOGY

A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain

(2017) Simone Treiger Sredni et al.   PEDIATRIC BLOOD & CANCER

Inhibition of polo-like kinase 4 (PLK4): a new therapeutic option for rhabdoid tumors and pediatric medulloblastoma

(2017) Simone Treiger Sredni et al.   Oncotarget

Synthesis and biological evaluation of (E)-4-(3-arylvinyl-1H-indazol-6-yl)pyrimidin-2-amine derivatives as PLK4 inhibitors for the treatment of breast cancer

(2017) Zhihao Liu et al.   RSC Advances

Small Molecule Supplements Improve Cultured Megakaryocyte Polyploidization by Modulating Multiple Cell Cycle Regulators

(2017) Xiaojing Zou et al.   Biomed Research International

Axitinib (AG-013736) in patients with metastatic melanoma: A phase II study

(2017) J. P. Fruehauf et al.   JOURNAL OF CLINICAL ONCOLOGY

Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery

(2016) Travis T. Wager et al.   ACS Chemical Neuroscience

Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors

(2016) Jonathon Torchia et al.   CANCER CELL

Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes

(2016) Pascal D. Johann et al.   CANCER CELL

Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer

(2016) Timothy P. Heffron   JOURNAL OF MEDICINAL CHEMISTRY

Recurrent genetic defects in classical Hodgkin lymphoma cell lines

(2016) S. David Hudnall et al.   LEUKEMIA & LYMPHOMA

Aurora-A Kinase: A Potent Oncogene and Target for Cancer Therapy

(2016) Min Yan et al.   MEDICINAL RESEARCH REVIEWS

Atypical teratoid/rhabdoid tumors—current concepts, advances in biology, and potential future therapies

(2016) Michael C. Frühwald et al.   NEURO-ONCOLOGY

Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts

(2016) Ines Lohse et al.   Oncotarget

Targeting cancer with kinase inhibitors

(2015) Stefan Gross et al.   JOURNAL OF CLINICAL INVESTIGATION

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study

(2015) Bohuslav Melichar et al.   LANCET ONCOLOGY

Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis

(2015) Jonathon Torchia et al.   LANCET ONCOLOGY

Centrosome function and assembly in animal cells

(2015) Paul T. Conduit et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children

(2015) Cynthia Wetmore et al.   NEURO-ONCOLOGY

Rhabdoid Tumor Predisposition Syndrome

(2015) Simone T. Sredni et al.   PEDIATRIC AND DEVELOPMENTAL PATHOLOGY

Autoinhibition and relief mechanism for Polo-like kinase 4

(2015) Joseph E. Klebba et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Reversible centriole depletion with an inhibitor of Polo-like kinase 4

(2015) Y. L. Wong et al.   SCIENCE

MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors

(2015) Todd B. Sells et al.   ACS Medicinal Chemistry Letters

Polo-like Kinase 4 Inhibition: A Strategy for Cancer Therapy?

(2014) Andrew J. Holland et al.   CANCER CELL

Functional Characterization of CFI-400945, a Polo-like Kinase 4 Inhibitor, as a Potential Anticancer Agent

(2014) Jacqueline M. Mason et al.   CANCER CELL

Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance

(2014) Mihaela Marina   Frontiers in Bioscience-Landmark

Mutation inPLK4, encoding a master regulator of centriole formation, defines a novel locus for primordial dwarfism

(2014) Ranad Shaheen et al.   JOURNAL OF MEDICAL GENETICS

The Discovery of Polo-Like Kinase 4 Inhibitors: Identification of (1R,2S)-2-(3-((E)-4-(((cis)-2,6-Dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5′-methoxyspiro[cyclopropane-1,3′-indolin]-2′-one (CFI-400945) as a Potent, Orally Active Antitumor Agent

(2014) Peter B. Sampson et al.   JOURNAL OF MEDICINAL CHEMISTRY

The Discovery of Polo-Like Kinase 4 Inhibitors: Design and Optimization of Spiro[cyclopropane-1,3′[3H]indol]-2′(1′H)-ones as Orally Bioavailable Antitumor Agents

(2014) Peter B. Sampson et al.   JOURNAL OF MEDICINAL CHEMISTRY

PLK4 overexpression and its effect on centrosome regulation and chromosome stability in human gastric cancer

(2014) Kazuya Shinmura et al.   MOLECULAR BIOLOGY REPORTS

Mutations in PLK4, encoding a master regulator of centriole biogenesis, cause microcephaly, growth failure and retinopathy

(2014) Carol-Anne Martin et al.   NATURE GENETICS

Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007–2011

(2014) Quinn T. Ostrom et al.   NEURO-ONCOLOGY

Causes and consequences of centrosome abnormalities in cancer

(2014) S. A. Godinho et al.   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes

(2014) Robert Huether et al.   Nature Communications

The Role of Chromatin Remodeling in Medulloblastoma

(2013) David T. W. Jones et al.   BRAIN PATHOLOGY

Study of the gene expression and microRNA expression profiles of malignant rhabdoid tumors originated in the brain (AT/RT) and in the kidney (RTK)

(2013) Alex T. Grupenmacher et al.   CHILDS NERVOUS SYSTEM

Medulloblastoma molecular dissection

(2013) Marc Remke et al.   CURRENT OPINION IN ONCOLOGY

The Discovery of PLK4 Inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as Novel Antiproliferative Agents

(2013) Radoslaw Laufer et al.   JOURNAL OF MEDICINAL CHEMISTRY

Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): Favorable activity of targeting EGFR- ErbB2 signaling with lapatinib

(2013) Anjali Singh et al.   Molecular Oncology

Transitioning from genotypes to epigenotypes: Why the time has come for medulloblastoma epigenomics

(2013) N.V. Batora et al.   NEUROSCIENCE

Axitinib for the Management of Metastatic Renal Cell Carcinoma

(2013) Bernard Escudier et al.   Drugs in research & development

Discovery of a Highly Potent, Orally Active Mitosis/Angiogenesis Inhibitor R1530 for the Treatment of Solid Tumors

(2013) Jin-Jun Liu et al.   ACS Medicinal Chemistry Letters

Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma

(2012) Adrian M. Dubuc et al.   ACTA NEUROPATHOLOGICA

The autoregulated instability of Polo-like kinase 4 limits centrosome duplication to once per cell cycle

(2012) A. J. Holland et al.   GENES & DEVELOPMENT

A Clinical Overview of Centrosome Amplification in Human Cancers

(2012) Jason Yongsheng Chan   International Journal of Biological Sciences

Targeting Aurora Kinase A enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells

(2012) Sujatha Venkataraman et al.   JOURNAL OF NEURO-ONCOLOGY

Downregulation of Polo-Like Kinase 4 in Hepatocellular Carcinoma Associates with Poor Prognosis

(2012) Lili Liu et al.   PLoS One

The Structure of the Plk4 Cryptic Polo Box Reveals Two Tandem Polo Boxes Required for Centriole Duplication

(2012) Lauren K. Slevin et al.   STRUCTURE

The Causes and Consequences of Polyploidy in Normal Development and Cancer

(2011) Teresa Davoli et al.   Annual Review of Cell and Developmental Biology

Centrosomes and cilia in human disease

(2011) Mónica Bettencourt-Dias et al.   TRENDS IN GENETICS

Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties

(2010) Travis T. Wager et al.   ACS Chemical Neuroscience

Aurora B is dispensable for megakaryocyte polyploidization, but contributes to the endomitotic process

(2010) L. Lordier et al.   BLOOD

Polyploidy: The Link Between Senescence and Cancer

(2010) G. Mosieniak et al.   CURRENT PHARMACEUTICAL DESIGN

Polo-like kinase 4 kinase activity limits centrosome overduplication by autoregulating its own stability

(2010) Andrew J. Holland et al.   JOURNAL OF CELL BIOLOGY

Plk4 trans-autophosphorylation regulates centriole number by controlling  TrCP-mediated degradation

(2010) G. Guderian et al.   JOURNAL OF CELL SCIENCE

Poly(cyclopropenone)s: Formal Inclusion of the Smallest Hückel Aromatic into π-Conjugated Polymers#

(2010) Patricia A. Peart et al.   JOURNAL OF ORGANIC CHEMISTRY

The Genetic Landscape of the Childhood Cancer Medulloblastoma

(2010) D. W. Parsons et al.   SCIENCE

Polo-like kinase 4: the odd one out of the family

(2010) James E Sillibourne et al.   Cell Division

KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation

(2009) Y. Shiotsu et al.   BLOOD

Autophosphorylation of Polo-like Kinase 4 and Its Role in Centriole Duplication

(2009) James E. Sillibourne et al.   MOLECULAR BIOLOGY OF THE CELL

Targeting protein kinases in central nervous system disorders

(2009) Laura K. Chico et al.   NATURE REVIEWS DRUG DISCOVERY

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

(2008) K. W. Pratz et al.   BLOOD

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

(2008) D. D. Hu-Lowe et al.   CLINICAL CANCER RESEARCH

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

(2008) Ezra E.W. Cohen et al.   JOURNAL OF CLINICAL ONCOLOGY